Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adc Therapeutics Sa
(NY:
ADCT
)
2.790
-0.140 (-4.78%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adc Therapeutics Sa
< Previous
1
2
3
4
5
6
7
8
9
Next >
ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q2 2024
August 06, 2024
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
August 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
July 30, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
A Preview Of ADC Therapeutics's Earnings
March 12, 2024
Via
Benzinga
7 Growth Stocks to Buy for Under $5 for Massive Gains
July 11, 2024
Although growth stocks under $5 are inherently risky and unpredictable, their very nature also facilitates robust upside potential.
Via
InvestorPlace
Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
July 08, 2024
Via
Benzinga
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
July 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
June 27, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
June 13, 2024
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy.
Via
InvestorPlace
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
June 03, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 15, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
May 09, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 06, 2024
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
May 06, 2024
Via
Benzinga
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
May 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
May 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
May 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
May 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Medifast Reports Mixed Results, Joins Coursera, Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
April 30, 2024
Via
Benzinga
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
April 04, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
April 03, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
April 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday
March 13, 2024
U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
March 13, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
March 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
March 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Earnings Scheduled For March 13, 2024
March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.